<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126316</url>
  </required_header>
  <id_info>
    <org_study_id>19424A</org_study_id>
    <nct_id>NCT05126316</nct_id>
  </id_info>
  <brief_title>A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen</brief_title>
  <official_title>Multiple-dose Safety, Pharmacokinetic and Pharmacodynamic Trial, in Subjects With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this trial is to learn more about the safety of repeated dosing with Lu&#xD;
      AG09222. The trial doctors will keep track of the participant's overall health by asking them&#xD;
      how they are and by analyzing blood and urine samples.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 6, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline (Day 1) up to Week 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve in the Last Dosing Interval (AUC0-τ) of Lu AG09222</measure>
    <time_frame>Up to 96 hours post last dose on Days 57 to 61; and on Days 64, 71, 78, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Lu AG09222</measure>
    <time_frame>Predose on Days 1 and 57; up to 96 hours post last dose on Days 57 to 61; and on Days 64, 71, 78, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Lu AG09222</measure>
    <time_frame>Predose on Days 1 and 57; up to 96 hours post last dose on Days 57 to 61; and on Days 64, 71, 78, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half-Life of Lu AG09222</measure>
    <time_frame>Predose on Days 1 and 57; up to 96 hours post last dose on Days 57 to 61; and on Days 64, 71, 78, and 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Wheal-Reaction Area at 20 and 120 Minutes After Allergen Challenge</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 8 in Flare-Reaction Area at 20 and 120 Minutes After Allergen Challenge</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Lu AG09222 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lu AG09222 injection at a low dose level 3 times with 4 weeks between each administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AG09222 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Lu AG09222 injection at a high dose level 3 times with 4 weeks between each administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to Lu AG09222 injection 3 times with 4 weeks between each administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG09222</intervention_name>
    <description>Lu AG09222 will be administered per schedule specified in the arm description.</description>
    <arm_group_label>Lu AG09222 High Dose</arm_group_label>
    <arm_group_label>Lu AG09222 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a body mass index (BMI) ≥18.0 and ≤30 kilograms (kg)/square meter&#xD;
             (m^2) at the screening visit.&#xD;
&#xD;
          -  The participant has a clinical history of grass pollen allergic rhinitis of at least 2&#xD;
             years' duration as diagnosed by a physician.&#xD;
&#xD;
          -  The participant has a positive specific immunoglobulin E (IgE) (defined as ≥class 2,&#xD;
             ≥0.70 kilounits [kU]/liter [L]) against Phleum pratense at screening.&#xD;
&#xD;
          -  The participant has a positive skin prick test with a wheal size ≥3 mm to Phleum&#xD;
             pratense at screening.&#xD;
&#xD;
          -  The participant is, in the opinion of the investigator, generally healthy based on&#xD;
             medical history (despite the allergic rhinitis), a physical examination, vital signs,&#xD;
             an electrocardiogram (ECG), and the results of the clinical chemistry, haematology,&#xD;
             urinalysis, serology, and other laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has received sublingual or subcutaneous immunotherapy with Phleum&#xD;
             pratense within the last 5 years.&#xD;
&#xD;
          -  The participant is receiving ongoing treatment with any allergy immunotherapy product.&#xD;
&#xD;
          -  The participant has a clinically relevant history of symptomatic (seasonal or&#xD;
             perennial) allergy caused by an allergen source overlapping with the allergen&#xD;
             challenge period.&#xD;
&#xD;
          -  The participant has taken disallowed medication or received a COVID-19 vaccination&#xD;
             within the protocol-specified amount of time before Day 1.&#xD;
&#xD;
          -  The participant has a relevant history of systemic allergic reaction, for example&#xD;
             anaphylaxis with cardiorespiratory symptoms, generalized urticaria, or severe facial&#xD;
             angioedema, which in the opinion of the investigator may constitute an increased&#xD;
             safety concern.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>H. Lundbeck A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Pancras Clinical Research</name>
      <address>
        <city>London</city>
        <zip>EC2Y 8EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

